Identification of apolipoproteinA1 reduction in the polycystic kidney by proteomics analysis of the Mxi1-deficient mouse

被引:11
|
作者
Yoo, Kyung Hyun [1 ]
Kim, Yo Na [2 ]
Lee, Min Joo [1 ]
Seong, Je Kyung [2 ]
Park, Jong Hoon [1 ]
机构
[1] Sookmyung Womens Univ, Dept Biol Sci, Seoul 140742, South Korea
[2] Seoul Natl Univ, Coll Vet Med, Lab Dev Biol & Genom, Seoul, South Korea
关键词
ApolipoproteinA1; Autosomal dominant polycystic kidney disease; Inflammation; Mxi1; Renal fibrosis; NECROSIS-FACTOR-ALPHA; A-I; TGF-BETA; MXI1; LIPOPROTEIN(A); INACTIVATION; ACTIVATION; EXPRESSION; MUTATION; DISEASE;
D O I
10.1002/pmic.200800753
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Autosomal dominant polycystic kidney disease is one of the most common human monogenic diseases in which extensive epithelial-lined cysts develop in kidney and other organs. Affected kidneys are not only characterized by the formation of cysts, but also by changes associated with the extracellular matrix and interstitial inflammation, which can progress to fibrosis and loss of renal function. Mxi1 protein, which is a c-myc antagonist, may be essential in controlling cellular growth and differentiation. Previously, multiple tubular cysts were observed in kidney of Mxi1-deficient mice aged 6 months and more. Presently, 2-DE and MALDI-TOF MS was employed to identify the differentially expressed proteins in the kidney. Several proteins were identified, among them, apolipoproteinA1 which is a major component of the high-density lipoprotein complex and has anti-inflammation effects, was significantly decreased in the Mxi1-deficient mouse. We confirm the development of inflammation and renal fibrosis and the expression of extracellular matrix molecules including transforming growth factor were also increased in cystic kidney. These results indicate that expression of proteins related with inflammation and renal fibrosis changes by Mxi1 inactivation in polycystic kidney.
引用
收藏
页码:3824 / 3832
页数:9
相关论文
共 46 条
  • [31] Novel Method for Genomic Analysis of PKD1 and PKD2 Mutations in Autosomal Dominant Polycystic Kidney Disease
    Tan, Ying-Cai
    Blumenfeld, Jon D.
    Anghel, Raluca
    Donahue, Stephanie
    Belenkaya, Rimma
    Balina, Marina
    Parker, Thomas
    Levine, Daniel
    Leonard, Debra G. B.
    Rennert, Hanna
    HUMAN MUTATION, 2009, 30 (02) : 264 - 273
  • [32] Proteomic Analysis of Rap1A GTPase Signaling-Deficient C57BL/6 Mouse Pancreas and Functional Studies Identify an Essential Role of Rap1A in Pancreas Physiology
    Shahwar, Durrey
    Baqai, Sadaf
    Khan, Faisal
    Khan, M. Israr
    Javaid, Shafaq
    Hameed, Abdul
    Raza, Aisha
    Uddin, Sadaf Saleem
    Hazrat, Hina
    Rahman, M. Hafizur
    Musharraf, Syed Ghulam
    Chotani, Maqsood A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (15)
  • [33] Identification of novel mutations of PKD1 gene in Chinese patients with autosomal dominant polycystic kidney disease by targeted next-generation sequencing
    Yang, Tao
    Meng, Yan
    Wei, Xiaoming
    Shen, Jiandong
    Zhang, Mingrong
    Qi, Chen
    Wang, Chundan
    Liu, Jiayin
    Ma, Minrui
    Huang, Shangzhi
    CLINICA CHIMICA ACTA, 2014, 433 : 12 - 19
  • [34] Autosomal dominant polycystic kidney disease: Comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients
    Audrezet, Marie-Pierre
    Cornec-Le Gall, Emilie
    Chen, Jian-Min
    Redon, Sylvia
    Quere, Isabelle
    Creff, Joelle
    Benech, Caroline
    Maestri, Sandrine
    Le Meur, Yann
    Ferec, Claude
    HUMAN MUTATION, 2012, 33 (08) : 1239 - 1250
  • [35] Molecular genetic analysis of PKHD1 by next-generation sequencing in Czech families with autosomal recessive polycystic kidney disease
    Obeidova, Lena
    Seeman, Tomas
    Elisakova, Veronika
    Reiterova, Jana
    Puchmajerova, Alena
    Stekrova, Jitka
    BMC MEDICAL GENETICS, 2015, 16
  • [36] Proteomics Analysis of CA1 Region of the Hippocampus in Pre-, Progression and Pathological Stages in a Mouse Model of the Alzheimer's Disease
    Gurel, Busra
    Cansev, Mehmet
    Koc, Cansu
    Ocalan, Busra
    Cakir, Aysen
    Aydin, Sami
    Kahveci, Nevzat
    Ulus, Ismail Hakki
    Sahin, Betul
    Basar, Merve Karayel
    Baykal, Ahmct Tarik
    CURRENT ALZHEIMER RESEARCH, 2019, 16 (07) : 613 - 621
  • [37] Early treatment with 2-deoxy-D-glucose reduces proliferative proteins in the kidney and slows cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease (PKD)
    Atwood, Daniel
    He, Zhibin
    Miyazaki, Makoto
    Hailu, Frehiwet
    Klawitter, Jelena
    Edelstein, Charles L.
    CELLULAR SIGNALLING, 2024, 123
  • [38] Characterisation of transcription factor profiles in polycystic kidney disease (PKD): identification and validation of STAT3 and RUNX1 in the injury/repair response and PKD progression
    Chiara Formica
    Tareq Malas
    Judit Balog
    Lotte Verburg
    Peter A. C. ‘t Hoen
    Dorien J. M. Peters
    Journal of Molecular Medicine, 2019, 97 : 1643 - 1656
  • [39] Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis
    Rupesh Raina
    Linda Lou
    Bruce Berger
    Beth Vogt
    Angelique Sao-Mai Do
    Robert Cunningham
    Pauravi Vasavada
    Karin Herrmann
    Katherine Dell
    Michael Simonson
    BMC Nephrology, 17
  • [40] Identification of TPD52 and DNAJB1 as two novel bile biomarkers for cholangiocarcinoma by iTRAQ-based quantitative proteomics analysis
    Ren, Hongyue
    Luo, Mingxu
    Chen, Jinzhong
    Zhou, Yanming
    Li, Xiumei
    Zhan, Yanyan
    Shen, Dongyan
    Chen, Bo
    ONCOLOGY REPORTS, 2019, 42 (06) : 2622 - 2634